HIGHLIGHTS
- who: Mohamed Mahameed from the (UNIVERSITY) have published the paper: The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors, in the Journal: (JOURNAL)
- what: The authors show that GSK414 inhibits KIT signaling at sub-micromolar concentrations, which are typically used to inhibit PERK. While clinically the ability to target simultaneously a few kinases may offer therapeutic advantages, particularly for cancer treatment, for research purposes this confounds mechanistic understanding. This study demonstrated Official journal of the Cell Death Differentiation Association that inhibition of ABL by imatinib, also a potent KIT inhibitor, affected IRE1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.